Efsubaglutide Alfa
LIGHT
Shanghai Yinnuo Pharmaceutical Technology Co · Phase 2 · Completed · Enrollment 50
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Efsubaglutide Alfa 5mg | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 7.5mg | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 10mg | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 15mg | n/r | n/r | n/r | n/r |
| Efsubaglutide Alfa 20mg | n/r | n/r | n/r | n/r |
Not shown
- Efsubaglutide Alfa 5mg: endpoint not reported
- Efsubaglutide Alfa 7.5mg: endpoint not reported
- Efsubaglutide Alfa 10mg: endpoint not reported
- Efsubaglutide Alfa 15mg: endpoint not reported
- Efsubaglutide Alfa 20mg: endpoint not reported